Literature DB >> 33904893

Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients.

Marissa Li1, Moritz Binder2, Terra Lasho2, Alejandro Ferrer2, Naseema Gangat2, Aref Al-Kali2, Abhishek Mangaonkar2, Michelle Elliott2, Mark Litzow2, William Hogan2, Animesh Pardanani2, Alexandra Wolanskyj-Spinner2, Matthew Howard3, Rebecca L King3, Mithun Shah2, Hassan Alkhateeb2, Kebede Begna2, Ayalew Tefferi2, Christy Finke2, Jennifer Oliveira3, Rhett Ketterling3, Horatiu Olteanu3, Mrinal M Patnaik2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33904893      PMCID： PMC8095155          DOI： 10.1182/bloodadvances.2020003976

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  14 in total

1.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

Review 2.  Myelodysplastic Syndromes.

Authors:  Mario Cazzola
Journal:  N Engl J Med       Date:  2020-10-01       Impact factor: 91.245

3.  Dynamics of clonal evolution in myelodysplastic syndromes.

Authors:  Hideki Makishima; Tetsuichi Yoshizato; Kenichi Yoshida; Mikkael A Sekeres; Tomas Radivoyevitch; Hiromichi Suzuki; Bartlomiej Przychodzen; Yasunobu Nagata; Manja Meggendorfer; Masashi Sanada; Yusuke Okuno; Cassandra Hirsch; Teodora Kuzmanovic; Yusuke Sato; Aiko Sato-Otsubo; Thomas LaFramboise; Naoko Hosono; Yuichi Shiraishi; Kenichi Chiba; Claudia Haferlach; Wolfgang Kern; Hiroko Tanaka; Yusuke Shiozawa; Inés Gómez-Seguí; Holleh D Husseinzadeh; Swapna Thota; Kathryn M Guinta; Brittney Dienes; Tsuyoshi Nakamaki; Shuichi Miyawaki; Yogen Saunthararajah; Shigeru Chiba; Satoru Miyano; Lee-Yung Shih; Torsten Haferlach; Seishi Ogawa; Jaroslaw P Maciejewski
Journal:  Nat Genet       Date:  2016-12-19       Impact factor: 38.330

Review 4.  Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.

Authors:  Mrinal M Patnaik; Terra Lasho
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

5.  Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias.

Authors:  Abhishek A Mangaonkar; Alejandro Ferrer; Filippo Pinto E Vairo; Margot A Cousin; Ryan J Kuisle; Naseema Gangat; William J Hogan; Mark R Litzow; Tammy M McAllister; Eric W Klee; Konstantinos N Lazaridis; A Keith Stewart; Mrinal M Patnaik
Journal:  Mayo Clin Proc       Date:  2019-06-27       Impact factor: 7.616

6.  SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.

Authors:  Mrinal M Patnaik; Terra L Lasho; Janice M Hodnefield; Ryan A Knudson; Rhett P Ketterling; Guillermo Garcia-Manero; David P Steensma; Animesh Pardanani; Curtis A Hanson; Ayalew Tefferi
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

Review 7.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

8.  ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Authors:  M M Patnaik; R Itzykson; T L Lasho; O Kosmider; C M Finke; C A Hanson; R A Knudson; R P Ketterling; A Tefferi; E Solary
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

9.  Practical recommendations for reporting Fine-Gray model analyses for competing risk data.

Authors:  Peter C Austin; Jason P Fine
Journal:  Stat Med       Date:  2017-09-15       Impact factor: 2.373

10.  Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.

Authors:  Siddhartha Jaiswal; Pradeep Natarajan; Alexander J Silver; Christopher J Gibson; Alexander G Bick; Eugenia Shvartz; Marie McConkey; Namrata Gupta; Stacey Gabriel; Diego Ardissino; Usman Baber; Roxana Mehran; Valentin Fuster; John Danesh; Philippe Frossard; Danish Saleheen; Olle Melander; Galina K Sukhova; Donna Neuberg; Peter Libby; Sekar Kathiresan; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2017-06-21       Impact factor: 91.245
View more
  3 in total

Review 1.  Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms.

Authors:  Talha Badar; Timothy Chlon
Journal:  Curr Hematol Malig Rep       Date:  2022-07-04       Impact factor: 4.213

2.  Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms.

Authors:  Mithun Vinod Shah; Abhishek A Mangaonkar; Kebede H Begna; Hassan B Alkhateeb; Patricia Greipp; Ahmad Nanaa; Michelle A Elliott; William J Hogan; Mark R Litzow; Kristen McCullough; Ayalew Tefferi; Naseema Gangat; Mrinal M Patnaik; Aref Al-Kali; Rong He; Dong Chen
Journal:  Blood Cancer J       Date:  2022-07-08       Impact factor: 9.812

3.  Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients.

Authors:  Jonathan Chiou; Allison Chiou; Rong He; Dong Chen; Constance P Chen; Caroline Spethman; Kurt R Bessonen; Jennifer L Oliveira; Phuong L Nguyen; Kaaren K Reichard; James D Hoyer; Simon D Althoff; Dana J Roh; Mechelle A Miller; Ji Yuan; Horatiu Olteanu; Kebede Begna; Ayalew Tefferi; Hassan Alkhateeb; Mrinal M Patnaik; Mark R Litzow; Aref Al-Kali; David S Viswanatha
Journal:  Blood Cancer J       Date:  2022-01-25       Impact factor: 11.037
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.